amenamevir

A novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2. Amenamenir stabilizes the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
012320102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
INTRODUCTION Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compound available for the treatment of varicella-zoster… (More)
Is this relevant?
2017
2017
Amenamevir is a potent helicase-primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2017
2017
INTRODUCTION Amenamevir is a nonnucleoside antiherpes virus compound available for treating herpes zoster infections. Four… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
  • table 5
Is this relevant?
Review
2017
Review
2017
Valacyclovir and famciclovir enabled successful systemic therapy for treating herpes simplex virus (HSV) and varicella zoster… (More)
Is this relevant?
2016
2016
Amenamevir is a novel drug that targets the viral helicase-primase complex. While dose-dependent efficacy had been observed in… (More)
  • table 1
  • table 2
  • figure 6
Is this relevant?
2014
2014
Amenamevir is the international non-proprietary name for ASP2151 synthesized by Astellas Pharma, Inc. It is a structurally novel… (More)
Is this relevant?
2013
2013
ASP2151 (amenamevir) is a helicase-primase complex inhibitor with antiviral activity against herpes simplex virus HSV-1, HSV-2… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
2013
2013
ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus… (More)
Is this relevant?
2012
2012
ASP2151 is an antiherpes agent targeting the helicase-primase complex of herpes simplex virus (HSV)-1, HSV-2, and varicella… (More)
Is this relevant?
2010
2010
OBJECTIVES To evaluate and describe the anti-herpesvirus effect of ASP2151, amenamevir, a novel non-nucleoside oxadiazolylphenyl… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?